Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma
A. G. Raufi, I. Pellicciotta, C. Palermo, S. Sastra, A. Chen, E. Alouani, C. Maurer, M. May, A. Iuga, R. Rabadan, K. P. Olive, G. A. Manji
This study shows that combining gemcitabine with CXCR4 inhibitors and anti-PD1 therapy improves immune response and survival in pancreatic cancer models.
bioRxiv · Dec 24, 2023 · PreprintCancer Biology